Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

Dokukina et al., NCT07157007, NCT07157007, Jan 2026
Early treatmentRCT · NCT07157007 · 50 patients · multinational
Ratutrelvir for COVID-19
Dokukina et al. NCT07157007 · January 2026
Outcome
Improvement
Relative Risk · 95% CI
Recovery
14%0.86 · 0.76–0.97
00.511.52+
← Ratutrelvir
reduces riskRatutrelvir
increases risk →
Improved recovery with ratutrelvir
p = 0.014 Trial compares with paxlovid, results vs. placebo may differ
Interim results showing improved time-to-sustained symptom alleviation and resolution with ratutrelvir.
Important missing comments or errors? Let us know.
risk of no recovery, 14.3% lower, RR 0.86, p = 0.01, treatment 32, control 18.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Dokukina et al., 13 Jan 2026, Randomized Controlled Trial, multiple countries, preprint, 1 author, this trial compares with another treatment - results may be better when compared to placebo, trial NCT07157007 (history).
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0